Maxcyte (MXCT) Share-based Compensation (2020 - 2026)

Maxcyte (MXCT) has reported Share-based Compensation for 7 consecutive years, with $8.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Share-based Compensation fell 58.28% year-over-year to $8.1 million in Q2 2026; TTM through Jun 2026 was $8.1 million, a 58.28% decrease from a year earlier, with the FY2025 full-year figure at $13.6 million, down 3.45% from the prior year.
• Share-based Compensation was $8.1 million for Q2 2026 at Maxcyte, up from $6.2 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $19.5 million in Q2 2025 and troughed at $706000.0 in Q4 2025.
• A 5-year average of $5.8 million and a median of $4.0 million in 2024 frame the typical range for Share-based Compensation.
• The widest YoY moves for Share-based Compensation: up 186.59% in 2025, down 77.47% in 2025.
• Over 5 years, Share-based Compensation stood at $3.1 million in 2022, then grew by 14.62% to $3.6 million in 2023, then retreated by 12.31% to $3.1 million in 2024, then plunged by 77.47% to $706000.0 in 2025, then jumped by 1051.98% to $8.1 million in 2026.
• The last three Share-based Compensation figures came in at $8.1 million (Q2 2026), $6.2 million (Q1 2026), and $706000.0 (Q4 2025), per Business Quant data.